BRIEF HISTORY OF THYROID FINE-NEEDLE ASPIRATION
===============================================

Shortly after Söderström in Sweden described thyroid fine-needle aspiration (FNA) cytology in 1952, it was introduced to Japan \[[@b1-jptm-2017-09-29],[@b2-jptm-2017-09-29]\]. In as early as 1972, Toriya published his first report on thyroid FNA cytology (in Japanese with an English abstract) from Ito Hospital (a thyroid center in Tokyo, Japan) \[[@b3-jptm-2017-09-29]\] where more than 1,000 surgical procedures for thyroid disease were carried out every year. His cytological diagnostic criteria were descriptive and similar to those for pathological diagnosis of surgical specimens. In 2005, Toriya \[[@b4-jptm-2017-09-29]\] reported his results and cytological-histological correlations in 1,702 surgically treated Japanese patients. He found 68 patients (4.0% of those receiving surgical treatment) in the indeterminate category, including 39 with benign lesions and 29 with malignancies, and the risk of malignancy (ROM) was 42.6% in the indeterminate category \[[@b4-jptm-2017-09-29]\]. In that report, he divided the indeterminate category into two subcategories (favor benign and favor malignant). Among 28 patients in the favor malignant sub-category, 16 had malignancy (4 papillary thyroid carcinomas \[PTCs\] and 12 follicular thyroid carcinomas \[FTCs\]) and the ROM was 57.1%. Among 40 patients in the favor benign subcategory, 13 had malignancy (3 PTCs and 10 FTCs) and the ROM was 32.5% \[[@b4-jptm-2017-09-29]\]. This principle to sub-classify indeterminate nodules into low-risk and high-risk categories was similar to the Bethesda System, but the actual ROMs obtained by Toriya \[[@b4-jptm-2017-09-29]\] in surgically treated nodules were higher than the implied ROMs for the atypia of undetermined significance (AUS)/follicular lesions of uncertain significance (FLUS) (5%--15%) and follicular neoplasm (FN)/suspicious for follicular neoplasm (15%--30%) categories estimated by the Bethesda system textbook \[[@b5-jptm-2017-09-29]\].

FINE-NEEDLE ASPIRATION THYROID CYTOLOGY: SAMPLING AND INTERPRETATION
====================================================================

In Japan, the clinician (endocrinologist, endocrine surgeon, or head and neck surgeon) generally performs FNA cytology at an outpatient clinic and FNA sampling by cytopathologists is unusual. Ultrasonography (US) is widely available and inexpensive (it costs only 35 U.S. dollars, about 10 U.S. dollars \[30%\] paid by patients and 25 U.S. dollars covered by the Japanese national health insurance system). Thus, US-guided FNA is preferred by most clinicians. Pathologists in Japan usually have dual certification; they are certified for anatomical pathology by the Japanese Society of Pathology and also for cytopathology by the Japanese Society of Clinical Cytology (JSCC). One of the characteristics of Japanese cytology practice is that a significant number of cytopathologists have a second clinical speciality, such as gynecology, endocrine surgery, breast surgery, respiratory medicine, respiratory surgery, urology, dental surgery, etc. They usually make a cytological diagnosis after collecting the specimens themselves \[[@b6-jptm-2017-09-29]\]. Approximately half of all thyroid FNA samples are diagnosed at commercial laboratories by board-certified pathologists and the other half are assessed at hospitals by pathologists and doctors who are board-certified cytologists.

CYTOTECHNOLOGIST TRAINING PROGRAM AND JAPANESE SOCIETY OF CLINICAL CYTOLOGY CERTIFICATION
=========================================================================================

The JSCC holds examinations for qualification of cytotechnologists and those who pass are registered as JSCC certified cytotechnologists. There are two pathways to obtaining national board recognition as a medical technologist in Japan; candidates must complete either a 3-year course at a vocational school or a 4-year course at a medical technology school, after which graduates can sit the national examination for medical technologists. Those who obtain a national medical technology license can apply to sit the JSCC examination for cytotechnologists after working for one year at the cytology laboratory of a teaching hospital. More than 800 teaching hospitals in Japan provide education on cytological diagnosis and technical skills, along with cytology laboratory experience. There are also college level (4-year) schools whose graduates are eligible to sit the JSCC cytotechnologist examination without 1 year of practical experience, but these schools are fewer than 10 and they remain a minor pathway. JSCC certified cytotechnologists provide both technical assistance and cytology screening services in the cytology laboratories of most institutions in Japan and often play a leading role in a central laboratory.

PREPARATION AND STAINING OF THYROID CYTOLOGY SAMPLES
====================================================

A 22- or 23-gauge needle is often used instead of a 26- or 27- gauge needle, in combination with a 10-mL disposable syringe and a pistol-grip mechanical syringe holder. Local anesthesia is not provided. Two smear slides are usually prepared from one FNA specimen, and are fixed in 95% ethanol or an equivalent fixative. Wet-fixed smears with Papanicolaou stain are favored by most laboratories, although some cytopathologists prefer air-dried smears with Giemsa stain or Diff-Quik stain. Liquid-based cytology is used in some laboratories, but is not widely available. Examination of FNA needle washings (hormonal assays and other diagnostic markers) has recently become popular for confirmation of the cytological diagnosis.

Thyroid FNA cytology reporting systems in Japan
-----------------------------------------------

There are two sets of clinical guidelines for handling thyroid nodules. One is the *General Rules for the Description of Thyroid Cancer* (GRDTC) published by the Japanese Society of Thyroid Surgery (JSTS) in 2005 and updated in 2016 \[[@b7-jptm-2017-09-29]\]. It includes a reporting system for thyroid FNA cytology. The other is a national reporting system (the Japanese system) for thyroid FNA cytology that was included in the clinical guidelines published by the Japan Thyroid Association (JTA) in 2013 \[[@b8-jptm-2017-09-29],[@b9-jptm-2017-09-29]\]. The GRDTC reporting system was adapted from the Papanicoloau Society recommendations published in 1996 \[[@b10-jptm-2017-09-29]\], while the Japanese system was adapted from Toriya's diagnostic system developed at Ito Hospital in Japan, which is characterized by two or three subclassifications of the indeterminate category \[[@b8-jptm-2017-09-29],[@b9-jptm-2017-09-29]\]. The Japanese system initially classifies the lesions in indeterminate category into indeterminate A (follicular neoplasms without PTC-type nuclear features \[PTC-N\]) and indeterminate B (nodules with nuclear atypia). The indeterminate A is further classified into three subcategories: A1 (favor benign), A2 (borderline), and A3 (favor malignant) ([Table 1](#t1-jptm-2017-09-29){ref-type="table"}) \[[@b9-jptm-2017-09-29]\]. Although the Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) itself is rarely used in Japan, the GRDTC and JTA system tried to incorporate TBSRTC so that cytological diagnoses made with the GRDTC or Japanese system could be related to TBSRTC diagnoses, and even the JSTS recommended TBSRTC after significant modifications. The GRDTC system is widely used in Japan, but several high-volume thyroid surgery centers prefer the Japanese system because they want to stratify the ROM in patients with FN. The indication for surgery is judged comprehensively by risk assessment on the basis of cytological diagnosis, ultrasound findings, and clinical findings. The prototype of the Japanese system has been used to reduce unnecessary diagnostic thyroidectomy in patients with FN cytology at several thyroid centers, including Ito Hospital (Tokyo, Japan) and Kuma Hospital (Kobe, Japan). As a result, it is not mandatory for Japanese patients with FN to undergo diagnostic thyroidectomy, which is completely different from the management in Western countries.

Thyroid cytology classification according to the Japanese system
----------------------------------------------------------------

In the Japanese system, thyroid nodules are classified into six categories by cytological diagnosis (inadequate, benign, indeterminate A, indeterminate B, suspicious for malignancy, and malignant) ([Table 1](#t1-jptm-2017-09-29){ref-type="table"}, [Fig. 1](#f1-jptm-2017-09-29){ref-type="fig"}). Indeterminate A is a category for FN (equivalent to Bethesda IV, but excluding cases with PTC-N), which is divided into three subcategories (A1, A2, and A3) based on cytological findings and ROM. These cytological subcategories have an impact on making decisions about clinical management. The cytological features of indeterminate A are no colloid background, microfollicular growth, enlarged nuclei, 3-dimensional clusters, and high cellularity. Nodules that demonstrate prominent trabecular clusters, cellular atypia, loss of cellular polarity, loss of cohesiveness, and nuclear overlapping are classified as group A3 ([Fig. 2](#f2-jptm-2017-09-29){ref-type="fig"}), while those with sheet-like follicles, medium-sized follicles, and a low nucleus/cytoplasm ratio are classified as group A1 ([Fig. 3](#f3-jptm-2017-09-29){ref-type="fig"}). Group A2 is intermediate between groups A1 and A3. Oxyphilic follicular tumors are handled as a separate group from indeterminate A and do not undergo subclassification in the Japanese system. Indeterminate B consists of lesions with nuclear abnormalities that are difficult to distinguish between benign and malignant, and are differentiated from FN by the presence of worrisome PTC-N. Lesions with extremely equivocal findings of PTC or medullary thyroid carcinoma (MTC) may be classified into this category. Indeterminate B is almost equivalent to the Bethesda III (AUS/FLUS) category, but FLUS without PTC-N are excluded and classified as indeterminate A1 by the Japanese system. The other categories of the Japanese system (inadequate, benign, suspicious for malignancy, and malignant) are equivalent to those of TBSRTC ([Fig. 1](#f1-jptm-2017-09-29){ref-type="fig"}). A further modification of the Japanese system is classifying samples that only contain cyst fluid as benign because of an extremely low ROM \[[@b11-jptm-2017-09-29]\].

The Japanese system in clinical practice at Yamashita Thyroid Hospital
----------------------------------------------------------------------

There are differences in surgical indications between Western and Asian practice, and the indications vary even among the institutions in Japan.

At Yamashita Thyroid Hospital, the indications for surgery in patients with thyroid nodules are as follows. Patients with inadequate cytology are recommended to undergo repeat FNA cytology or follow-up examination at intervals of 6 to 12 months. US is routinely performed at each follow-up visit in these patients. If a follicular tumor or cancer is suspected by US during the follow-up, repeat FNA cytology is usually performed. Patients with benign cytology are usually recommended to have follow-up examination, but diagnostic thyroidectomy may be recommended when the tumor is larger than 4 cm in diameter. Patients with indeterminate A1 cytology receive either diagnostic thyroidectomy or observation based on US findings and tumor size. Patients with indeterminate A2 or A3 cytology are recommended to undergo diagnostic thyroidectomy unless the tumor is small (e.g. \< 1 cm in diameter). Although repeat FNA is recommended for patients with indeterminate B cytology, most patients with suspected malignancy according to US findings immediately undergo diagnostic thyroidectomy without repeat FNA. Patients with suspicious for malignancy or malignant cytology are recommended to undergo therapeutic thyroidectomy, but some patients with papillary microcarcinoma may be managed by observation, a so-called active surveillance \[[@b12-jptm-2017-09-29]-[@b14-jptm-2017-09-29]\].

At Yamashita Thyroid Hospital (Fukuoka, Japan), about 1,000 surgical procedures for thyroid disease are carried out every year, and the results of US-guided FNA cytology for 1,600 nodules from January 2015 to April 2016 are summarized in [Tables 2](#t2-jptm-2017-09-29){ref-type="table"} and [3](#t3-jptm-2017-09-29){ref-type="table"}. These tables show the correlation between cytological and histological diagnoses categorized according to either TBSRTC or the Japanese system. Because liquid-based cytology was not performed during this period, the frequency of Bethesda I (inadequate category) was high at 23.9% (382/1,600). The resection rate (RR), ROM in resected patients, and ROM in all patients receiving FNA are presented in [Table 2](#t2-jptm-2017-09-29){ref-type="table"}. Among 154 nodules classified as Bethesda IV (Indeterminate A), 75 nodules were A1, 29 nodules were A2, and 11 nodules were A3. Thirty-nine lesions were suspected to be oxyphilic follicular tumors and were separately classified as indeterminate A oxyphilic according to our original classification. The RR and ROM in each of these four subcategories are also listed in [Table 3](#t3-jptm-2017-09-29){ref-type="table"}. We were able to successfully stratify category A into subcategories A1, A2, and A3 according to the increase of ROM and RR, thus reducing unnecessary thyroidectomies in patients with indeterminate A (FN).

The correlation between cytological and histological diagnoses in patients who underwent FNA cytology and surgical follow-up at Yamashita Thyroid Hospital is presented in [Table 2](#t2-jptm-2017-09-29){ref-type="table"}. While PTC accounted for 98% of Bethesda VI, only two MTCs, one anaplastic thyroid carcinoma and one diffuse large B-cell lymphoma were included in this category. Similarly, PTC accounted for more than 90% of the malignant tumors in Bethesda V. FTC accounted for about 70% of the malignant tumors in Bethesda IV (indeterminate A), while follicular variant PTC accounted for 20%. In each indeterminate A subcategory (A1, A2, and A3), more than half of the malignant tumors had a histological diagnosis of FTC. In our hospital, the final histological diagnosis was FTC for the majority of malignancies in indeterminate A.

In 2015, Sugino *et al*. \[[@b15-jptm-2017-09-29]\] reported on the correlation between cytological and histological diagnosis in indeterminate A patients according to the Japanese system. They assessed 1,553 indeterminate A patients (4.3%) among 36,066 patients who underwent US-guided FNA thyroid cytology between 2005 and 2011 at Ito Hospital (Tokyo, Japan). Histological diagnosis of the primary thyroid tumor was available in 779 of the 1,553 patients with indeterminate A lesions. The overall RR was 50.2%, with the RR being 46.9% in A1, 55.4% in A2, and 65.1% in A3. The overall ROM was 34.5% in resected cases, while the ROM was 30.0% in resected A1 cases, 40.3% in A2, and 50.0% in A3. In addition, FTC accounted for about 75.5% of malignant tumors in indeterminate A patients, and 11 follicular variant PTCs (4.1%) were included in indeterminate A category. Their results are fairly consistent with our findings.

In conclusion, the Japanese system seems to direct high-risk patients with FN to surgery, while low-risk patients with FN are recommended for follow-up. FTC accounted for the majority of malignancies in Japanese patients with indeterminate A lesions who underwent diagnostic thyroidectomy, which is different from reports on Western patients \[[@b16-jptm-2017-09-29],[@b17-jptm-2017-09-29]\].

ANCILLARY TESTING, INCLUDING CORE BIOPSY
========================================

Core needle biopsy is rarely performed in thyroid patients in Japan; it may be used instead of open biopsy to confirm malignant lymphoma of the thyroid or undifferentiated carcinoma in inoperable cases. Molecular testing for *BRAF* mutation and other molecular alterations, as suggested in the 2015 guidelines of the American Thyroid Association \[[@b18-jptm-2017-09-29]\], may be used to triage patients with indeterminate nodules, but is not a common practice in Japan. As of 2017, it is only done for academic research \[[@b19-jptm-2017-09-29]\] because its use is not supported by the Japanese national health insurance system. On the other hand, measurement of thyroglobulin (Tg) and/or calcitonin in FNA needle washings is often used as a helpful diagnostic adjunct in patients with thyroid nodules or cervical tumors, as are serum tumor markers. When the needle aspirate is immediately fixed and submitted for cytological examination, the needle and syringe are washed with 0.5 mL of saline and the washings are also submitted for measurement of biochemical markers. The presence of Tg in the FNA needle washings suggests that the tumor originated from thyroid follicular cells. This method is useful for establishing the diagnosis of lymph node metastasis when samples are obtained from possible cervical metastases of well-differentiated thyroid carcinoma. In 1983, Miyauchi *et al*. \[[@b20-jptm-2017-09-29]\] (one of the leaders in the field of thyroid oncology in Japan and Asia) reported that the detection of very high thyroglobulin content in aspirates from cystic lymph nodes of the neck supported the diagnosis of metastatic PTC. This method is also applied to the diagnosis of MTC. Kudo (a colleague of Miyauchi) *et al*. \[[@b21-jptm-2017-09-29]\] reported that the measurement of calcitonin in FNA needle washings could identify MTC with a high sensitivity and specificity. This is the historical background that explains why the measurement of Tg and/or calcitonin in aspirates is preferred by endocrinologists and endocrine surgeons in Japan.

CONCLUSION
==========

In Japan, the clinician (endocrinologist, endocrine surgeon, or head and neck surgeon) usually performs FNA cytology at an outpatient clinic, while it is rarely done by pathologists, and US-guided FNA is common.

A 22- or 23-gauge needle is popular instead of a 26- or 27- gauge needle. Wet-fixed smears (95% ethanol) and Papanicolaou stain are favored by most laboratories in Japan.

The most popular reporting system for thyroid FNA cytology in Japan is the GRDTC adapted from the 1996 Papanicolaou Society recommendations. Although TBSRTC was introduced to replace the GRDTC, it has not yet become popular in Japan. The Japanese system is used at several high-volume thyroid surgery centers to stratify the ROM for FN nodules.

Cytological diagnoses made by the GRDTC or Japanese system correspond to those of TBSRTC.

At high-volume thyroid centers, the Japanese system has been useful for risk stratification in patients with FN nodules and it has reduced unnecessary diagnostic thyroidectomy.

The measurement of Tg and/or calcitonin in FNA needle washings is often used as a diagnostic adjunct in patients with possible cervical lymph node metastasis.
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![Correlation between the Japan Thyroid Association reporting system (the Japanese system) and the Bethesda System for Reporting Thyroid Cytopathology (TBSRTC). FN, follicular neoplasm.](jptm-2017-09-29f1){#f1-jptm-2017-09-29}

![Cytological findings of indeterminate A3. Cellular atypia, loss of cellular polarity, nuclear enlargement, and nuclear over-lapping are noted. The specimen was aspirated from a minimally invasive follicular carcinoma.](jptm-2017-09-29f2){#f2-jptm-2017-09-29}

![Cytological findings of indeterminate A1. Microfollicular clusters are seen. The nuclei are round and slightly small. The specimen was aspirated from a follicular adenoma.](jptm-2017-09-29f3){#f3-jptm-2017-09-29}

###### 

Cytological reporting system recommended in the 2013 Japanese guideline for management of thyroid nodules

  Diagnostic category                                                   Risk of malignancy (%)
  --------------------------------------------------------------------- ------------------------
  Inadequate (non-diagnostic)                                           10
  Normal or benign                                                      \< 1
  Indeterminate                                                         
   Indeterminate A (foliicular neoplasm)                                
   A-1: favor benign                                                    \< 15
   A-2: borderline                                                      15--30
   A-3: favor malignant                                                 40--60
   Indeterminate B (others: atypia in non-follicular pattern lesions)   40--60
  Suspicious for malignancy (not conclusive for malignancy)             \> 80
  Malignancy                                                            \> 99

###### 

Correlation between cytological and histological diagnoses in patients undergoing FNA cytology and surgical follow-up at Yamashita Thyroid Hospital from January 2015 to April 2016

        The Bethesda system         Surgery       Resection rate (%)   Histological diagnosis   ROM at surgery (%)   Overall ROM (%)                                                                                  
  ----- --------------------------- ------------- -------------------- ------------------------ -------------------- ----------------- ---- ---- --- ---- --- --------------- ---- --- --- --- --- --- --- --- ------ ------
  I     Inadequate                  382 (24)      63                   16.5                     35                   0                 11   2    2   1    0   8               2    0   2   0   0   0   0   0   20.6   3.4
  II    Benign                      626 (39)      89                   14.2                     67                   4                 5    0    2   1    0   8               0    0   0   0   0   0   2   0   12.4   1.8
  III   AUS                         171 (11)      47                   27.5                     22                   0                 16   2    0   0    0   0               2    0   0   0   0   0   4   1   14.9   4.1
  IV    Follicular neoplasm         154 (9.6)     85                   55.2                     21                   0                 26   17   0   12   2   0               2    2   0   2   1   0   0   0   24.7   13.6
  V     Suspicious for malignancy   52 (3.3)      39                   75                       3                    0                 0    0    0   1    0   27              4    0   3   0   0   0   1   0   92.3   69.2
  VI    Malignant                   215 (13)      199                  92.6                     0                    0                 0    0    0   0    0   188             5    0   2   0   2   1   0   1   100    92.6
                                    1,600 (100)   522                  32.6                     148                  4                 58   21   4   15   2   231             15   2   7   2   3   1   7   2   55     17.9
                                                                                                                     Benign 235                               Malignant 287                                           

FNA, fine-needle aspiration; AN, adenomatous nodule; H, Hashimoto's thyroiditis; FA, follicular adenoma; FA oxy, oxyphilic follicular adenoma; FTC, follicular thyroid carcinoma; FTC oxy, follicular thyroid carcinoma, oxyphilic variant; PTC, papillary thyroid carcinoma; PTC fol, papillary thyroid carcinoma, follicular variant; PTC macrofol, papillary thyroid carcinoma, macrofollicular variant; WDC-NOS, well-differentiated carcinoma, not otherwise specified; MTC, medullary thyroid carcinoma; ATC, anaplastic thyroid carcinoma; MALT, mucosa-associated lymphoid tissue; DLBCL, diffuse large B-cell lymphoma; ROM, risk of malignancy; AUS, atypia of undetermined significance.

###### 

Resection rate and risk of malignancy in patients with indeterminate A cytology (including oxyphilic follicular neoplasm)

  Cytological classification   No. (%)     Malignancy   ROM at histology (%)   Overall ROM (%)   Histological classification (malignancy)                            
  ---------------------------- ----------- ------------ ---------------------- ----------------- ------------------------------------------ ---- ---- ---- ---- ---- ----
  Indeterminate A1             75 (48.7)   33 (44)      4                      12.1              5.3                                        2    1    \-   1    \-   \-
  Indeterminate A2             29 (18.8)   20 (68.9)    10                     50                34.5                                       7    \-   \-   1    2    \-
  Indeterminate A3             11 (7.1)    10 (90.9)    6                      60                54.5                                       3    \-   2    \-   \-   1
  Indeterminate A oxyphilic    39 (25.3)   22 (56.4)    1                      4.5               2.6                                        \-   1    \-   \-   \-   \-
                               154 (100)   85 (55.2)    21                     24.7              13.6                                       12   2    2    2    2    1

FNA, fine-needle aspiration; ROM, risk of malignancy; FTC, follicular thyroid carcinoma; FTC oxy, follicular thyroid carcinoma, oxyphilic variant; PTC fol, papillary thyroid carcinoma, follicular variant; PTC macrofol, papillary thyroid carcinoma, macrofollicular variant; WDC-NOS, well-differentiated carcinoma, not otherwise specified; MTC, medullary thyroid carcinoma.
